Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00490789
NCT00490789UnknownPhase 2

A Trial of the Efficacy and Safety of Sirolimus(Rapamycin)Therapy for Renal Angiomyolipmoas in Patients With Tuberous Sclerosis Complex and Sporadic Lymphangioleiomyomatosis

Cardiff University6 sites in 1 country14 target enrollmentStarted: October 2005Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Phase 2
Enrollment
14
Locations
6
Primary Endpoint
longest diameter of renal angiomyolipomas assessed by MRI scan, toxicity graded by National Cancer Institute's Common Terminology Criteria for Adverse Events v3.0
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The purpose of this study is to determine the safety and efficacy of the mTOR inhibitor sirolimus as a treatment for renal angiomyolipomas in patients with tyberous sclerosis complex or sporadic lymphangioleiomyomatosis.

Detailed Description

Inherited mutations of the TSC1 or TSC2 gene cause tuberous sclerosis while acquired (somatic) mutations of either gene are associated with sporadic lymphangioleiomyomatosis (LAM). Renal angiomyolipomas are a feature of both disorders. TSC1 and TSC2 regulate signalling through the mammalian target of rapamycin (mTOR) pathway. Inhibition of mTOR may result in a decrease in size of TSC 1/2 assciated lesions. We are treating patients with tuberous sclerosis or sporadic LAM with the mTOR inhibitor rapamycin in a non-randomised, open label pilot study of safety and efficacy. Change in size of renal angiomyolipomas is the primary end point

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •If female, documentation of negative pregnancy test prior to enrolment.
  • •Participants, including males, must use an effective form of contraception, whilst taking sirolimus and for twelve weeks after stopping the drug
  • •One or more renal angiomyolipomata of at least two centimetres or greater in largest diameter
  • •Adequate renal function :glomerular filtration rate > 40 ml/min
  • •Clinically definite diagnosis of tuberous sclerosis (modified Gomez criteria) or sporadic LAM (biopsy-proven or compatible high resolution chest CT scan and respiratory function tests.)
  • •Signed and dated informed consent

Exclusion Criteria

  • •History of non-compliance or inability to give informed consent
  • •Significant haematological or hepatic abnormality (i.e. transaminase levels > 150 i.u./L serum albumin < 30 g/L, haematocrit< 30%, platelets < 100,000/ mm3, adjusted absolute neutrophil count < 1,500/mm3, total WBC < 3,000/ mm3)
  • •Greater than 1 g proteinuria daily
  • •Multiple bilateral AMLs, where individual lesions cannot be distinguished
  • •Renal haemorrhage within preceding year
  • •In those who have had a renal haemorrhage, known conservatively managed renal aneurysm(s) greater than 10mm
  • •Patients who have had embolisation for AML(s) within the preceding 6 months
  • •Patients who are unable to walk 100 metres on the flat
  • •Continuous requirement for supplemental oxygen
  • •Patients who have had or are being considered for organ transplant
  • •Uncontrolled hyperlipidaemia
  • •Intercurrent infection at initiation of Sirolimus
  • •Surgery within last 2 months
  • •Pregnant or lactating women
  • •Use of an investigational drug within the last 30 days
  • •Change in anti epileptic drug medication within the last 3 months
  • •Likely to need vaccination e.g. for travel during the course of the trial (except for influenza vaccine in patients with LAM)
  • •Current usage of strong inhibitors of CYP3AE ( such as ketoconazole, voriconazole, itraconazole, tilithromycin or clarithromycin) or strong inducers (such as rifampicin or rifabutin)

Outcomes

Primary Outcomes

longest diameter of renal angiomyolipomas assessed by MRI scan, toxicity graded by National Cancer Institute's Common Terminology Criteria for Adverse Events v3.0

Time Frame: assessments at baseline and 2,6,12 and 24 months

toxicity graded by National Cancer Institute's Common Terminology Criteria for Adverse Events

Time Frame: throughout study

Secondary Outcomes

  • respiratory function tests (FEV1, FVC, DLCO), cognitive function (memory, executive skills)(2 years)

Investigators

Sponsor Class
Other

Study Sites (6)

Loading locations...

Similar Trials

Recruiting
Phase 2
Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous MalformationsArteriovenous Malformations
NCT02042326Centre Hospitalier Universitaire, Amiens50
Completed
Phase 1
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity CancerRecurrent Fallopian Tube CancerRecurrent Ovarian Epithelial CancerRecurrent Primary Peritoneal Cavity CancerStage IIA Fallopian Tube CancerStage IIA Ovarian Epithelial CancerStage IIA Primary Peritoneal Cavity CancerStage IIB Fallopian Tube CancerStage IIB Ovarian Epithelial CancerStage IIB Primary Peritoneal Cavity CancerStage IIC Fallopian Tube CancerStage IIC Ovarian Epithelial CancerStage IIC Primary Peritoneal Cavity CancerStage IIIA Fallopian Tube CancerStage IIIA Ovarian Epithelial CancerStage IIIA Primary Peritoneal Cavity CancerStage IIIB Fallopian Tube CancerStage IIIB Ovarian Epithelial CancerStage IIIB Primary Peritoneal Cavity CancerStage IIIC Fallopian Tube CancerStage IIIC Ovarian Epithelial CancerStage IIIC Primary Peritoneal Cavity CancerStage IV Fallopian Tube CancerStage IV Ovarian Epithelial CancerStage IV Primary Peritoneal Cavity Cancer
NCT01536054Roswell Park Cancer Institute7
Withdrawn
Phase 1
Sirolimus for Improving Social Abilities in People With PTEN Germline MutationsPTEN Gene MutationPTEN Hamartoma Tumor SyndromePTEN Hamartoma Syndrome
NCT06080165Stanford University
Recruiting
Phase 1
Sirolomus Adjuvant Treatment of Focal Refractory Epilepsy (SATFRE)Epilepsy, Drug Resistant
NCT06719791Xuanwu Hospital, Beijing15
Completed
Early Phase 1
Sirolimus, Tacrolimus and Short Course Methotrexate for Prevention of Acute GVHD in Recipients of Mismatched Unrelated Donor Allogeneic Stem Cell TransplantationStem Cell Transplantation
NCT00612274Yale University26
Trial of Efficacy and Safety of Sirolimus... | Clinical Trial